Repligen enters its third-quarter report with an unusual setup. Management has raised its full-year outlook twice in a row, and the stock has rewarded that confidence. Yet the company also told investors plainly that this quarter would be the weakest of the year for gross margin. The question on October 27 is whether a quarter that was billed as a mix-driven soft patch arrives on schedule, or whether it shows that the demand recovery behind the stock's run is fragile.
The Street is looking for adjusted earnings of $0.46 per share, unchanged from a year ago, on revenue of about $206.6 million, up 9.5%. Revenue growth near double digits paired with flat earnings is not a sign of trouble. It reflects management's own warning. Product mix should weigh on gross margin, a one-time compensation benefit that helped the second quarter will not repeat, and spending on sales, R&D and IT is ramping. Against second-quarter results of $0.54 per share on $204.1 million in revenue, consensus implies modest sequential sales growth and a clear dip in profitability. That gap is roughly what management prepared investors for.
The full-year comparison is more revealing. Repligen now guides to adjusted EPS of $2.03 to $2.09 on revenue of $813 million to $835 million. Consensus revenue of about $824 million sits near the middle of that range, but the $1.99 EPS consensus falls below the low end of management's earnings guidance. Analysts appear to be discounting part of the raised margin outlook, which now calls for 190 to 220 basis points of adjusted operating margin expansion. A clean third quarter paired with a reaffirmed or raised EPS range would challenge that skepticism directly.
Operationally, the strongest growth drivers need to keep pulling their weight. Proteins grew about 50% last quarter on PureLight, Avitide custom resins and growth factors. Analytics grew more than 30% on the SoloVPE Plus upgrade cycle. Chromatography grew at a low double-digit pace against a full-year target of 20% or better, so it needs to accelerate. Filtration is the known weak spot. Management said gene therapy softness, timing issues at two ATF customers and the Polymem divestiture would persist through this quarter before normalizing in the fourth. Anything worse than slight growth there, or any sign that the ATF customer problems are spreading beyond inventory and site readiness, would undercut the idea that these headwinds are temporary. Breadth matters too. Emerging biotech had grown at a high-teens rate for five straight quarters, Asia-Pacific grew about 40%, and new modalities posted their best quarter since early 2025.
The newer catalysts deserve scrutiny. Management said a third capital equipment RFP win was weeks away and pointed to a sequential rise in equipment orders that is building 2027 backlog. Confirmation of that win and continued order momentum would support the onshoring story. Investors should also look for updates on the BioLife cell therapy acquisition, which management expects to add $0.05 per share in its first year and $0.25 in its second. How BioLife figures into guidance once it closes will shape 2027 models.
Sentiment has warmed, moving from 17.8% bearish before the last report to just 5.6% bearish now. The stock is up 25.6% since that report against a 3.3% gain for the S&P 500. At $175.42 it trades well above its 200-day average of $144.19 but about 12% below its post-earnings high of $198.87, so some of the early enthusiasm has already cooled. Ultimately, this report hinges on whether the margin dip stays contained and filtration stabilizes as promised. If both hold and the full-year outlook stays intact, Repligen's recovery story survives its toughest quarter. If either falls short, the two raises will look less like momentum and more like a high bar.